Literature DB >> 27157321

Development and Validation of a Mass Spectrometry-Based Assay for the Molecular Diagnosis of Mucin-1 Kidney Disease.

Brendan Blumenstiel1, Matthew DeFelice2, Ozge Birsoy3, Anthony J Bleyer4, Stanislav Kmoch5, Todd A Carter2, Andreas Gnirke2, Kendrah Kidd4, Heidi L Rehm3, Lucienne Ronco2, Eric S Lander2, Stacey Gabriel2, Niall J Lennon2.   

Abstract

Mucin-1 kidney disease, previously described as medullary cystic kidney disease type 1 (MCKD1, OMIM 174000), is an autosomal dominant tubulointerstitial kidney disease recently shown to be caused by a single-base insertion within the variable number tandem repeat region of the MUC1 gene. Because of variable age of disease onset and often subtle signs and symptoms, clinical diagnosis of mucin-1 kidney disease and differentiation from other forms of hereditary kidney disease have been difficult. The causal insertion resides in a variable number tandem repeat region with high GC content, which has made detection by standard next-generation sequencing impossible to date. The inherently difficult nature of this mutation required an alternative method for routine detection and clinical diagnosis of the disease. We therefore developed and validated a mass spectrometry-based probe extension assay with a series of internal controls to detect the insertion event using 24 previously characterized positive samples from patients with mucin-1 kidney disease and 24 control samples known to be wild type for the variant. Validation results indicate an accurate and reliable test for clinically establishing the molecular diagnosis of mucin-1 kidney disease with 100% sensitivity and specificity across 275 tests called.
Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27157321     DOI: 10.1016/j.jmoldx.2016.03.003

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  9 in total

Review 1.  Genomic medicine for kidney disease.

Authors:  Emily E Groopman; Hila Milo Rasouly; Ali G Gharavi
Journal:  Nat Rev Nephrol       Date:  2018-01-08       Impact factor: 28.314

2.  Utility of Genomic Testing after Renal Biopsy.

Authors:  Susan L Murray; Anthony Dorman; Katherine A Benson; Dervla M Connaughton; Caragh P Stapleton; Neil K Fennelly; Claire Kennedy; Ciara A McDonnell; Kendrah Kidd; Sarah M Cormican; Louise A Ryan; Peter Lavin; Mark A Little; Anthony J Bleyer; Brendan Doyle; Gianpiero L Cavalleri; Friedhelm Hildebrandt; Peter J Conlon
Journal:  Am J Nephrol       Date:  2019-12-10       Impact factor: 3.754

3.  Noninvasive Immunohistochemical Diagnosis and Novel MUC1 Mutations Causing Autosomal Dominant Tubulointerstitial Kidney Disease.

Authors:  Martina Živná; Kendrah Kidd; Anna Přistoupilová; Veronika Barešová; Mathew DeFelice; Brendan Blumenstiel; Maegan Harden; Peter Conlon; Peter Lavin; Dervla M Connaughton; Hana Hartmannová; Kateřina Hodaňová; Viktor Stránecký; Alena Vrbacká; Petr Vyleťal; Jan Živný; Miroslav Votruba; Jana Sovová; Helena Hůlková; Victoria Robins; Rebecca Perry; Andrea Wenzel; Bodo B Beck; Tomáš Seeman; Ondřej Viklický; Sylvie Rajnochová-Bloudíčková; Gregory Papagregoriou; Constantinos C Deltas; Seth L Alper; Anna Greka; Anthony J Bleyer; Stanislav Kmoch
Journal:  J Am Soc Nephrol       Date:  2018-07-02       Impact factor: 10.121

4.  Single molecule real time sequencing in ADTKD-MUC1 allows complete assembly of the VNTR and exact positioning of causative mutations.

Authors:  Andrea Wenzel; Janine Altmueller; Arif B Ekici; Bernt Popp; Kurt Stueber; Holger Thiele; Alois Pannes; Simon Staubach; Eduardo Salido; Peter Nuernberg; Richard Reinhardt; André Reis; Patrick Rump; Franz-Georg Hanisch; Matthias T F Wolf; Michael Wiesener; Bruno Huettel; Bodo B Beck
Journal:  Sci Rep       Date:  2018-03-08       Impact factor: 4.379

5.  Identification of a novel UMOD mutation (c.163G>A) in a Brazilian family with autosomal dominant tubulointerstitial kidney disease.

Authors:  L B Lopes; C C Abreu; C F Souza; L E R Guimaraes; A A Silva; F Aguiar-Alves; K O Kidd; S Kmoch; A J Bleyer; J R Almeida
Journal:  Braz J Med Biol Res       Date:  2018-03-01       Impact factor: 2.590

6.  Autosomal dominant tubulointerstitial kidney disease genotype and phenotype correlation in a Chinese cohort.

Authors:  Kunjing Gong; Min Xia; Yaqin Wang; Na Wang; Ying Liu; Victor Wei Zhang; Hong Cheng; Yuqing Chen
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379

7.  Plasma Mucin-1 (CA15-3) Levels in Autosomal Dominant Tubulointerstitial Kidney Disease due to MUC1 Mutations.

Authors:  Petr Vylet'al; Kendrah Kidd; Hannah C Ainsworth; Drahomíra Springer; Alena Vrbacká; Anna Přistoupilová; Rebecca P Hughey; Seth L Alper; Niall Lennon; Steven Harrison; Maegan Harden; Victoria Robins; Abbigail Taylor; Lauren Martin; Katrice Howard; Ibrahim Bitar; Carl D Langefeld; Veronika Barešová; Hana Hartmannová; Kateřina Hodaňová; Tomáš Zima; Martina Živná; Stanislav Kmoch; Anthony J Bleyer
Journal:  Am J Nephrol       Date:  2021-06-07       Impact factor: 3.754

8.  Genetic Testing of the mucin 1 gene-Variable Number Tandem Repeat Single Cytosine Insertion Mutation in a Chinese Family with Medullary Cystic Kidney Disease.

Authors:  Nuo Si; Ke Zheng; Jie Ma; Xiao-Lu Meng; Xue-Mei Li; Xue Zhang
Journal:  Chin Med J (Engl)       Date:  2017-10-20       Impact factor: 2.628

9.  Autosomal dominant tubulointerstitial kidney disease (ADTKD) in Ireland.

Authors:  S Cormican; D M Connaughton; C Kennedy; S Murray; M Živná; S Kmoch; N K Fennelly; P O'Kelly; K A Benson; E T Conlon; G Cavalleri; C Foley; B Doyle; A Dorman; M A Little; P Lavin; K Kidd; A J Bleyer; P J Conlon
Journal:  Ren Fail       Date:  2019-11       Impact factor: 2.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.